BOSTON ( TheStreet) -- Welcome 2010! To get the year started, here's a calendar of important, potentially stock-moving biotech events for January: Jan. 7 Forest Labs ( FRX) investor/analyst meeting. Teva Pharmaceuticals ( TEVA) investor/analyst meeting. Jan. 10-14 28th Annual J.P. Morgan Healthcare Conference. Jan. 11 Food and Drug Administration advisory committee meeting for Forest Labs' Bystolic in congestive heart failure. Jan. 11-14 International Association for the Study of Lung Cancer meeting. Jan. 14 Ilumina ( ILMN) investor/analyst meeting. Jan. 16 FDA approval decision date for Mannkind's ( MNKD) Afresa, an inhaled insulin for diabetes. Jan. 18 FDA approval decision date for OSI Pharmaceuticals' ( OSIP) Tarceva in first-line (maintenance) non-small cell lung cancer. Jan. 22 FDA approval decision date for Acorda Therapeutics' ( ACOR) Amaya for multiple sclerosis Jan. 22-24 American Society for Clinical Oncology Gastrointestinal Cancers Symposium. Important clinical trials with potential data readouts or other biotech events expected in January: Spectrum Pharmaceuticals ( SPPI) meeting with FDA to discuss complete response letter for colon cancer drug Fusilev. FDA approval decision for Novo Nordisk's ( NVO) diabetes drug Victoza. FDA approval decision for Auxillium Pharmaceuticals' ( AUXL) Xiaflex for Dupuytren's Contracture. (With Pfizer ( PFE) as marketing partner.) Synta Pharmaceuticals ( SNTA) -- Results from a phase II study of apilimod in rheumatoid arthritis. -- Reported by Adam Feuerstein in Boston.